Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination

Inclusion Criteria: * Subjects with advanced, metastatic or refractory solid malignancy who are not candidates for standard therapy. For subject with metastatic breast cancer, prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate bone marrow, cardiac, liver, renal and pancreatic function * Predicted life expectancy of at least 12 weeks Exclusion Criteria: * Prolonged corrected QT (QTc), defined as QTcF (QT interval corrected for heart rate according to Fridericia) interval \> 450 msec at screening by central reader * Cardiac disease: Congestive heart failure \> NYHA Class II; subjects must not have unstable angina (angina symptoms at rest) or new-onset angina (began within the last 3 months) or myocardial infarction within the past 6 months; cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * Arterial or venous thrombi, including cerebrovascular accident and myocardial infarction in the past 6 months * Pulmonary hemorrhage event ≥ CTCAE (common toxicity criteria for adverse events) Grade 2 within 4 weeks * Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks * Chemotherapy, hormonal therapy, investigational drugs, or radiotherapy within the last 28 days and/or not recovered (\< Grade 1) from prior therapy. Start of study treatment is allowed within less than 28 days of the prior therapy provided that 5 half-lives of the prior treatment drug(s) have elapsed. * Use of medication that may prolong QTc